These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16633367)

  • 21. Optimizing randomized phase II trials assessing tumor progression.
    Stone A; Wheeler C; Carroll K; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor response evaluation in oncology: current update.
    Shanbhogue AK; Karnad AB; Prasad SR
    J Comput Assist Tomogr; 2010 Jul; 34(4):479-84. PubMed ID: 20657213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
    Lencioni R; Llovet JM
    Semin Liver Dis; 2010 Feb; 30(1):52-60. PubMed ID: 20175033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New guidelines to evaluate the response to treatment in solid tumors].
    Duffaud F; Therasse P
    Bull Cancer; 2000 Dec; 87(12):881-6. PubMed ID: 11174117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endpoints for assessing drug activity in clinical trials.
    Pazdur R
    Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Critical evaluation of disease stabilization as a measure of activity of systemic therapy: lessons from trials with arms in which patients do not receive active treatment.
    Le Tourneau C; Paoletti X; Coquan E; Sablin MP; Zoubir M; Tannock IF
    J Clin Oncol; 2014 Jan; 32(3):260-3. PubMed ID: 24297942
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical trials in drug development: a minimalistic approach.
    Verweij J
    Curr Opin Oncol; 2012 May; 24(3):332-7. PubMed ID: 22343389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stable disease is a valid end point in clinical trials.
    Tolcher AW
    Cancer J; 2009; 15(5):374-8. PubMed ID: 19826356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiologic measurements of tumor response to treatment: practical approaches and limitations.
    Suzuki C; Jacobsson H; Hatschek T; Torkzad MR; Bodén K; Eriksson-Alm Y; Berg E; Fujii H; Kubo A; Blomqvist L
    Radiographics; 2008; 28(2):329-44. PubMed ID: 18349443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early oncology clinical trial design in the era of molecular-targeted agents.
    Brunetto AT; Kristeleit RS; de Bono JS
    Future Oncol; 2010 Aug; 6(8):1339-52. PubMed ID: 20799878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Veterinary oncology clinical trials: design and implementation.
    Thamm DH; Vail DM
    Vet J; 2015 Aug; 205(2):226-32. PubMed ID: 25582798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents.
    Kocherginsky M; Cohen EE; Karrison T
    J Biopharm Stat; 2009; 19(3):524-9. PubMed ID: 19384693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A call for change in anticancer drug evaluation.
    Cvitkovic E
    Eur J Cancer; 1997 Jan; 33 Suppl 2():S3-7. PubMed ID: 9166088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiological monitoring of the treatment of solid tumors in practice.
    Ganten MK; Ganten TM; Schlemmer HP
    Rofo; 2014 May; 186(5):466-73. PubMed ID: 24563412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
    El-Maraghi RH; Eisenhauer EA
    J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour growth rates and RECIST criteria in early drug development.
    Gomez-Roca C; Koscielny S; Ribrag V; Dromain C; Marzouk I; Bidault F; Bahleda R; Ferté C; Massard C; Soria JC
    Eur J Cancer; 2011 Nov; 47(17):2512-6. PubMed ID: 21763126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Newer phase II trial designs gaining ground.
    Benowitz S
    J Natl Cancer Inst; 2007 Oct; 99(19):1428-9. PubMed ID: 17895467
    [No Abstract]   [Full Text] [Related]  

  • 38. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving the evaluation of new cancer treatments: challenges and opportunities.
    Rothenberg ML; Carbone DP; Johnson DH
    Nat Rev Cancer; 2003 Apr; 3(4):303-9. PubMed ID: 12671669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria.
    Trillet-Lenoir V; Freyer G; Kaemmerlen P; Fond A; Pellet O; Lombard-Bohas C; Gaudin JL; Lledo G; Mackiewicz R; Gouttebel MC; Moindrot H; Boyer JD; Chassignol L; Stremsdoerfer N; Desseigne F; Moreau JM; Hedelius F; Moraillon A; Chapuis F; Bleuse JP; Barbier Y; Heilmann MO; Valette PJ
    Br J Radiol; 2002 Nov; 75(899):903-8. PubMed ID: 12466256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.